RESUMEN
Resumen La cardiotoxicidad asociada al uso de quimioterapéuticos ha sido ampliamente corroborada a través de diversos estudios clínicos. En Costa Rica se han empezado a desarrollar Unidades Cardio-oncológicas en diversos centros médicos con el fin de detectar de manera precoz el efecto deletéreo cardiovascular asociado a los diferentes quimioterapéuticos. A con tinuación, se presenta un resumen de las manifestaciones clínicas cardiovasculares asociadas al uso de antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS)
Abstract Cardiotoxicity of anthracycline-type chemotherapeutics in the official list of medicines of the Caja Costarricense del Seguro Social Cardiotoxicity associated with the use of chemotherapy has been largely corroborated along multiple clinical trials. In Costa Rica, the development of Cardio-oncologic Units has begun recently in various medical centers with the purpose of achieving an early detection of the deleterious cardiovascular effect associated with different chemotherapeutics. This review consists of a summary of the clinical manifestations related to the use of anthracyclines available in the Costa Rican public health system.